Recordati details February treasury share sales and buy-back transactions

Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) just unveiled an announcement.

Recordati disclosed a series of February 2026 transactions involving its own shares, combining sales of treasury stock to beneficiaries of existing stock option plans with purchases executed under an ongoing buy-back programme. The sale transactions correspond to options exercised by employees or other beneficiaries at pre-set exercise prices, underscoring the company’s continued use of equity-based incentives while modestly reducing its treasury share balance.

In parallel, UBS Europe SE acted as intermediary on the Italian market to repurchase Recordati shares during the same period under a buy-back programme launched in December 2025. These purchases are part of a broader capital management strategy that can support earnings per share, provide stock for incentive plans and signal confidence in the company’s prospects, with implications for existing shareholders through potential changes in free float and capital allocation priorities.

The most recent analyst rating on (IT:REC) stock is a Buy with a EUR57.50 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.

More about Recordati Industria Chimica e Farmaceutica SPA

Recordati Industria Chimica e Farmaceutica is an Italian specialty pharmaceutical company based in Milan that develops and markets prescription medicines and other healthcare products. The group operates primarily in Europe with a focus on branded drugs and niche therapeutic areas, and its shares are listed on the Italian stock market under the ticker associated with ISIN IT0003828271.

Average Trading Volume: 336,401

Technical Sentiment Signal: Hold

Current Market Cap: €9.82B

Find detailed analytics on REC stock on TipRanks’ Stock Analysis page.